Legalization of medical cannabis linked to sharp drop in opioid use

A recent study published in the’American Journal of Health Economics provides new, solid evidence of the link between the legalization of medical cannabis and a marked decline in opioid prescriptions in the United States.

Conducted by researchers at the University of Georgia and the University of Colorado, this analysis is based on health insurance data from 15 to 20 million Americans per year, covering the period 2007–2020.

The results show that in states that have adopted laws on medical cannabis, the number of patients The number of patients receiving opioid prescriptions has decreased on average from 16 %, some states such as the Minnesota and New York showing discounts of more than 20 %. These declines were consistent across most demographic groups, regardless of gender, age, or ethnicity.

Consistent effects across all populations

This study is one of the first to provide evidence at the patient level on how the legalization of medical cannabis affects opioid prescribing patterns. The researchers noted that the impact was relatively uniform across the various subgroups, although certain populations, such as the cancer patients and Black patients without cancer, have seen an even greater decline in opioid use, exceeding 20 %.

Beyond the overall decline in prescriptions, the study also highlighted a reduction in the intensity of prescriptions : Not only did patients receive fewer opioid prescriptions, but the duration of their prescriptions was also shorter.

According to the authors, «we find that [medical cannabis laws] are associated with a significant reduction in opioid prescribing.» Among the states in question, the proportion of patients receiving opioid prescriptions fell by an average of 16 %, masking significant heterogeneity across states, with individual decreases reaching 22 %.”.

A Shift Toward Safer Options for Pain Management

Another key finding was the increase in prescriptions for NSAIDs (nonsteroidal anti-inflammatory drugs), suggesting a shift from opioids to safer alternatives for pain management following the adoption of medical cannabis programs.

«These findings confirm the potential of medical cannabis as a policy tool to reduce opioid use and promote safer pain management,» the authors said.

This substitution effect could have significant implications for public health. As opioid addiction and overdose deaths continue to plague the United States, the study’s findings reinforce the argument that Medical cannabis can serve as a harm-reduction measure, allowing patients and doctors to rely less on high-risk opioid painkillers.

Significant variations among states

While the overall trend in the 12 states included in the study was a clear fewer opioid prescriptions, the extent of the effect varied considerably. Some states, such as the’Illinois, saw negligible declines, while others, notably New York and the Minnesota, recorded declines of more than 20 %.

This variation highlights just how much the implementation strategies and policies specific to each state may influence the impact of legalization medical cannabis. Factors such as ease of access for patients, product availability, and physician participation likely play a role in these results.

The researchers conclude that medical cannabis laws are a valuable tool for policymakers seeking to combat the opioid crisis. Although the authors note that the study’s design does not allow for the establishment of a direct causal link, the robustness of the results—confirmed by several sensitivity analyses—reinforces, in their view, the value of considering cannabis-based policies as part of a comprehensive strategy for pain management and public health.

«Furthermore, our findings contribute to the broader debate on the role of medical cannabis in pain management and on how it can serve as a viable alternative to riskier or more dangerous medications, such as prescription opioid painkillers,» the study states.